ICI NOLVADEX PREVENTION STUDY FOR WOMEN AT RISK
ICI NOLVADEX PREVENTION STUDY FOR WOMEN AT RISK of breast cancer should be considered, National Cancer Institute Director Samuel Broder, MD, suggested at a Jan. 26 meeting of the NCI Cancer Prevention and Control Division's Board of Scientific Counselors. Broder suggested the board "discuss . . . a randomized, placebo-controlled study following tamoxifen . . . in a certain population of women who are at risk of breast cancer." He added that "there are pros and cons" for such a study. A nonsteroidal antiestrogenic hormone product, Nolvadex is indicated for treatment of metastatic breast cancer in postmenopausal women but not for prophylactic use. Last May NCI mailed to 12,000 physicians study results on the positive effects of tamoxifen as an adjuvant therapy in stage one, node negative breast cancer patients. "The ball is in your court," Broder told the board. "I could foresee by way of long speculation that we might be able to identify someone who does not have cancer but who does have some abnormality that we might be able to correct in advance." However, he cautioned that the question of safety regarding such a trial "is extremely important."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth